SF3B1 and acute myeloid leukemia: SF3B1 mutations are seen in AML with myelodysplasia‐related changes, but with the low VAF (4.3% ⟶ 2.5%) and eventual disappearance on the 4/2024 myeloid NGS, its role in disease progression and loss of response to VEN‐based therapy remains unknown.